Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's ...

Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...

Tonix's TNX-1500 Shows Promise In Preventing Organ Transplant Rejections Of Either Human Or Pig Organs; Autoimmune Diseases Also A Target Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed ...

Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries ...

Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and delivering innovative therapies for neurological and neurodegenerative diseases ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...